Stealth mRNA nanovaccines to control lymph node trafficking
Autor/a
Altres autors/es
Data de publicació
2024-08-22ISSN
1873-4995
Resum
mRNA-based vaccines symbolize a new paradigm shift in personalized medicine for the treatment of infectious and non-infectious diseases. However, the reactogenicity associated with the currently approved formulations limits their applicability in autoinflammatory disorders, such as tumour therapeutics. In this study, we present a delivery system showing controlled immunogenicity and minimal non-specific inflammation, allowing for selective delivery of mRNA to antigen presenting cells (APCs) within the medullary region of the lymph nodes. Our platform offers precise control over the trafficking of nanoparticles within the lymph nodes by optimizing stealth and targeting properties, as well as the subsequent opsonization process. By targeting specific cells, we observed a potent adaptive and humoral immune response, which holds promise for preventive and therapeutic anti-tumoral vaccines. Through spatial programming of nanoparticle distribution, we can promote robust immunization, thus improving and expanding the utilization of mRNA vaccines. This innovative approach signifies a remarkable step forward in the field of targeted nanomedicine.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
539 - Constitució física de la matèria
Paraules clau
zwitterionics
mRNA
Nanoparticles
Delivery systems
cancer
Reactogenicity
Pàgines
12 p.
Publicat per
Elsevier
Publicat a
Journal of Controlled Release. 2024;374:325-336
Número de l'acord de la subvenció
info:eu-repo/grantAgreement/ISCIII/PN I+D/AC22/00042
info:eu-repo/grantAgreement/MICIN i FEDER/Proyecto PID2021-125910OB-I00
info:eu-repo/grantAgreement/SUR del DEC/SGR/2021 SGR 00537
Aquest element apareix en la col·lecció o col·leccions següent(s)
Drets
© L'autor/a
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by-nc-nd/4.0/